×
About 3,653 results

ALLMedicine™ Gastrointestinal Cancers Center

Research & Reviews  881 results

Absence of association between CT-assessed skeletal muscle mass and long-term oncologic...
https://doi.org/10.1016/j.hpb.2022.04.009
HPB : the Official Journal of the International Hepato Pa... Meyer YM, Galjart B et. al.

May 14th, 2022 - Sarcopenia is associated with impaired short- and long-term outcomes in gastrointestinal cancers. Whether sarcopenia is associated with impaired survival after local therapy of Colorectal Cancer Liver Metastases (CRLM) remains controversial. This ...

Jejunal adenocarcinoma after biliopancreatic diversion. Report of a case.
https://doi.org/10.1016/j.orcp.2022.05.002
Obesity Research & Clinical Practice; Cossu ML, Fancellu A et. al.

May 14th, 2022 - The effects of bariatric surgery on the development of gastrointestinal cancers remain ill defined. We present a case of jejunal adenocarcinoma developing 19 years after biliopancreatic diversion (BPD) procedure according to Scopinaro's technique....

Acquisition of Blood and Tumor Tissue Samples From Patients With Gastrointestinal Cancer
https://clinicaltrials.gov/ct2/show/NCT01313442

May 13th, 2022 - BACKGROUND: Numerous recent therapeutic advances have changed standard treatment options for patients with GI cancer. These include newer chemotherapeutic agents in addition to established proof of principle for anti-angiogenic agents. The burden ...

A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Col...
https://clinicaltrials.gov/ct2/show/NCT03929666

May 11th, 2022 - Part 1 of the study will first evaluate the safety and tolerability of ZW25 plus standard first-line combination chemotherapy (XELOX, FP, or mFOLFOX6 for GEA; mFOLFOX6 with or without bevacizumab for CRC; and CisGem for BTC) and will confirm the r...

see more →

Guidelines  2 results

AGA Clinical Practice Update on Surveillance After Pathologically Curative Endoscopic S...
https://doi.org/10.1053/j.gastro.2021.08.058
Gastroenterology Wang AY, Hwang JH et. al.

Oct 26th, 2021 - The purpose of this American Gastroenterological Association (AGA) Institute Clinical Practice Update was to review the available evidence and provide expert advice regarding surveillance using endoscopy and other relevant modalities after removal...

Screening and surveillance in hereditary gastrointestinal cancers: Recommendations from...
https://doi.org/10.1016/j.ejca.2018.09.004
European Journal of Cancer (Oxford, England : 1990); Vangala DB, Cauchin E et. al.

Oct 21st, 2018 - Patients with hereditary gastrointestinal (GI) cancers represent a substantial fraction of the overall affected population. Although awareness for hereditary GI cancer syndromes is on the rise, identification of patients and measures of surveillan...

see more →

Drugs  1 results see all →

Clinicaltrials.gov  21 results

Acquisition of Blood and Tumor Tissue Samples From Patients With Gastrointestinal Cancer
https://clinicaltrials.gov/ct2/show/NCT01313442

May 13th, 2022 - BACKGROUND: Numerous recent therapeutic advances have changed standard treatment options for patients with GI cancer. These include newer chemotherapeutic agents in addition to established proof of principle for anti-angiogenic agents. The burden ...

A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Col...
https://clinicaltrials.gov/ct2/show/NCT03929666

May 11th, 2022 - Part 1 of the study will first evaluate the safety and tolerability of ZW25 plus standard first-line combination chemotherapy (XELOX, FP, or mFOLFOX6 for GEA; mFOLFOX6 with or without bevacizumab for CRC; and CisGem for BTC) and will confirm the r...

First Line Metastatic Pancreatic Cancer : 5FU/LV+Nal-IRI, Gemcitabine+Nab-paclitaxel or a Sequential Regimen of 2 Months 5FU/LV+Nal-IRI
https://clinicaltrials.gov/ct2/show/NCT03693677

Mar 24th, 2022 - Pancreatic cancer (PC) is the seventh cause from cancer and the fifth cause from cancer-related death in Europe. Nearly as many deaths occur from PC than the number of new cases diagnosed each year, reflecting the poor prognosis typically associat...

Predictors of Tumor Response and of Radiation Therapy Side Effects in Patients With Gastrointestinal Cancers
https://clinicaltrials.gov/ct2/show/NCT01445327

Feb 1st, 2022 - Background: Gastrointestinal (GI) carcinomas represent one of the most commonly diagnosed malignancies in the United States. A sensitive and specific marker of tumor persistence or recurrence would permit a more accurate determination of the appro...

Early Palliative Care in Patients With Metastatic Upper Gastrointestinal Cancers Treated With First-line Chemotherapy
https://clinicaltrials.gov/ct2/show/NCT02853474

Dec 21st, 2021 - Medical oncology is aimed to increase patient's survival, even at metastatic stages, in addition to disease-related and treatment-related symptoms. However, providing palliative care (PC) which includes symptoms management, nutritional support, ps...

see more →

News  556 results

BI 836880/Ezabenlimab Combo Had Limited Antitumor Activity, But Manageable Safety in Advanced MSS CRC
https://www.onclive.com/view/bi-836880-ezabenlimab-combo-had-limited-antitumor-activity-but-manageable-safety-in-advanced-mss-crc

May 2nd, 2022 - The VEGF/Ang2–targeting bispecific nanobody BI 836880, in combination with ezabenlimab (BI 754091), produced antitumor activity found to be comparable to that of available third-line therapy options in patients with advanced microsatellite stable ...

PD-L1 Test Debated in Gastroesophageal Cancer Immunotherapy
https://www.medscape.com/viewarticle/972445

Apr 20th, 2022 - Clinicians are struggling to make sense of conflicting regulations from the Food and Drug Administration and the European Medicines Agency on whether measuring programmed death–ligand 1 (PD-L1) is essential before prescribing checkpoint inhibitors...

PD-L1 test debated in gastroesophageal cancer immunotherapy
https://www.mdedge.com/hematology-oncology/article/253873/gastrointestinal-cancer/pd-l1-test-debated-gastroesophageal
Laird Harrison

Apr 19th, 2022 - Clinicians are struggling to make sense of conflicting regulations from the Food and Drug Administration and the European Medicines Agency on whether measuring programmed death–ligand 1 (PD-L1) is essential before prescribing checkpoint inhibitors.

Nivolumab/Ipilimumab Approved in Europe for Frontline PD-L1+ Advanced ESCC
https://www.onclive.com/view/nivolumab-ipilimumab-approved-in-europe-for-frontline-pd-l1-advanced-escc

Apr 5th, 2022 - The European Commission has approved the dual immunotherapy combination of nivolumab (Opdivo) and ipilimumab (Yervoy) for use in the frontline treatment of adult patients with unresectable advanced, recurrent or metastatic esophageal squamous cell...

'Eye-opening' Experience on the Other Side of the Hospital Bed
https://www.medscape.com/viewarticle/971119

Mar 29th, 2022 - The 5 days that she spent at her mother's bedside were eye-opening for an oncologist used to being on the other side of the clinician–patient relationship. "As a physician, I thought I had a unique perspective of things that were done well — and t...

see more →